US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SMITH-MIDLAND CORP

29.88

+1.595.62%

Volume:12.05K

Turnover:352.75K

Market Cap:158.50M

PE:20.61

High:30.13

Open:28.23

Low:28.23

Close:28.29

Loading ...

Overview Company News Filings

Polen US SMID Company Growth Strategy Sold Alarm.com Holdings (ALRM) Despite High-Quality Assessment

Polen US SMID Company Growth Strategy Sold its Unsuccessful Investment in Fox Factory Holding Corp. (FOXF) in Q4

Here’s Why Polen US SMID Company Growth Strategy Exited Euronet Worldwide (EEFT)

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference

NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference

CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SMID/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SMID","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SMID\",,,,,undefined,":{"symbol":"SMID","market":"US","secType":"STK","nameCN":"SMITH-MIDLAND CORP","latestPrice":29.88,"timestamp":1750104000000,"preClose":28.29,"halted":0,"volume":12054,"delay":0,"floatShares":4548821,"shares":5304606,"eps":1.45,"marketStatus":"Pre-Mkt","change":1.59,"latestTime":"06-17 09:22:19 EDT","open":28.23,"high":30.13,"low":28.23,"amount":352746.6637,"amplitude":0.067162,"askPrice":32,"askSize":3,"bidPrice":8.97,"bidSize":100,"shortable":3,"etf":0,"ttmEps":1.45,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1750167000000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":29.88,"postHourTrading":{"tag":"盘后","latestPrice":29.88,"preClose":29.88,"latestTime":"16:04 EDT","volume":147,"amount":4392.36,"timestamp":1750104246970},"volumeRatio":0.990696289287873},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SMID\",,,,,undefined,":{"symbol":"SMID","floatShares":4548821,"roa":"9.57%","roe":"20.22%","lyrEps":1.451124,"volumeRatio":0.990696289287873,"shares":5304606,"dividePrice":0,"high":30.13,"amplitude":0.067162,"preClose":28.29,"low":28.23,"week52Low":25.0301,"pbRate":"3.80","psRate":"2.02","week52High":51.96,"institutionHeld":0.6383,"latestPrice":29.88,"committee":0.941748,"eps":1.45,"divideRate":0,"volume":12054,"delay":0,"ttmEps":1.45,"open":28.23,"prevYearClose":44.46,"prevWeekClose":28.29,"prevMonthClose":30.14,"prevQuarterClose":31.07,"fiveDayClose":31.8,"twentyDayClose":32.64,"sixtyDayClose":32.99},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SMID\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2508975148","title":"Polen US SMID Company Growth Strategy Sold Alarm.com Holdings (ALRM) Despite High-Quality Assessment","url":"https://stock-news.laohu8.com/highlight/detail?id=2508975148","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508975148?lang=en_us&edition=fundamental","pubTime":"2025-02-03 21:04","pubTimestamp":1738587844,"startTime":"0","endTime":"0","summary":"Polen Capital, an investment management company, released its “Polen US SMID Company Growth Strategy” fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here. SMID cap stocks initially rose by more than 10% following November's U.S. Presidential election, in another volatile quarter. However, they relinquished nearly all of those gains in December, as the U.S. Federal Reserve signaled that interest rate cuts would occur more slowly than anticipated, with reductions expected to start in 2025. Against this backdrop, the fund returned 3.0% gross, and 2.7% net of fees compared to the Russell 2500 Growth Index return of 2.4%. In addition, you can check the fund’s top 5 holdings to find out its best picks for 2024.Polen US SMID Company Growth Strategy stated the following regarding Alarm.com Holdings, Inc.  in its Q4 2024 investor letter:. Inanother article, we discussed Alarm.com Holdings, Inc.  and shared The Brown Capital Management Small Company Fund's views on t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polen-us-smid-company-growth-130404955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4023","QLD","SMID","PSQ","SQQQ","MNQmain","NVIW.SI","TQQQ","TSYW.SI","QID","USJW.SI","USAW.SI","NQmain",".IXIC","ALRM"],"gpt_icon":1},{"id":"2508110404","title":"Polen US SMID Company Growth Strategy Sold its Unsuccessful Investment in Fox Factory Holding Corp. (FOXF) in Q4","url":"https://stock-news.laohu8.com/highlight/detail?id=2508110404","media":"Insider Monkey","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508110404?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:56","pubTimestamp":1738587391,"startTime":"0","endTime":"0","summary":"Polen Capital, an investment management company, released its “Polen US SMID Company Growth Strategy” fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here. SMID cap stocks initially rose by more than 10% following November's U.S. Presidential election, in another volatile quarter. However, they relinquished nearly all of those gains in December, as the U.S. Federal Reserve signaled that interest rate cuts would occur more slowly than anticipated, with reductions expected to start in 2025. Against this backdrop, the fund returned 3.0% gross, and 2.7% net of fees compared to the Russell 2500 Growth Index return of 2.4%. In addition, you can check the fund’s top 5 holdings to find out its best picks for 2024.Polen US SMID Company Growth Strategy stated the following regarding Fox Factory Holding Corp.  in its Q4 2024 investor letter:. Inanother article, we discussed Fox Factory Holding Corp.  and shared Conestoga Capital Advisors' views on the company in the pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polen-us-smid-company-growth-125631224.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSYW.SI","USJW.SI","IE00B64QTZ34.USD","NVIW.SI","QID","TQQQ",".IXIC","MNQmain","BK4124","SMID","PSQ","USAW.SI","SQQQ","FOXF","NQmain","QLD"],"gpt_icon":1},{"id":"2508104751","title":"Here’s Why Polen US SMID Company Growth Strategy Exited Euronet Worldwide (EEFT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2508104751","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508104751?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:53","pubTimestamp":1738587238,"startTime":"0","endTime":"0","summary":"Polen Capital, an investment management company, released its “Polen US SMID Company Growth Strategy” fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here. SMID cap stocks initially rose by more than 10% following November's U.S. Presidential election, in another volatile quarter. However, they relinquished nearly all of those gains in December, as the U.S. Federal Reserve signaled that interest rate cuts would occur more slowly than anticipated, with reductions expected to start in 2025. Against this backdrop, the fund returned 3.0% gross, and 2.7% net of fees compared to the Russell 2500 Growth Index return of 2.4%. In addition, you can check the fund’s top 5 holdings to find out its best picks for 2024.Polen US SMID Company Growth Strategy stated the following regarding Euronet Worldwide, Inc.  in its Q4 2024 investor letter:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-polen-us-smid-company-125358727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4227","MNQmain","QID","TSYW.SI","NQmain","NVIW.SI",".IXIC","EEFT","SMID","SQQQ","TQQQ","BK4106","USJW.SI","USAW.SI","PSQ","QLD"],"gpt_icon":1},{"id":"2507295793","title":"Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507295793","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507295793?lang=en_us&edition=fundamental","pubTime":"2025-01-31 21:00","pubTimestamp":1738328400,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Jan. 31, 2025  -- Erasca, Inc.,a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being held at the Lotte New York Palace in New York, New York. Management will participate in a fireside chat on Thursday, February 6, 2025, at 9:30 am Eastern Time and will also participate in one-on-one investor meetings.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/erasca-present-guggenheim-securities-smid-130000798.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4011","BK4139","SMID","BK4539","ERAS"],"gpt_icon":0},{"id":"2507637603","title":"Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507637603","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507637603?lang=en_us&edition=fundamental","pubTime":"2025-01-31 05:05","pubTimestamp":1738271100,"startTime":"0","endTime":"0","summary":"SAN CARLOS, Calif., Jan.  30, 2025  (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conse","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/30/3018412/0/en/Vaxcyte-to-Present-at-the-Guggenheim-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SMID","LU0053671581.USD","IE0009354923.USD","PCVX","BK4011"],"gpt_icon":0},{"id":"2507603464","title":"Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2507603464","media":"Newsfile","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507603464?lang=en_us&edition=fundamental","pubTime":"2025-01-31 05:00","pubTimestamp":1738270800,"startTime":"0","endTime":"0","summary":"Philadelphia, Pennsylvania and Oxford, United Kingdom-- - Adaptimmune Therapeutics plc , a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the Guggenheim Securities SMID Cap Biotech Conference this February.Fireside chat with Adrian Rawcliffe, CEO: February 6 at 3:00 p.m. EST. Adaptimmune ContactInvestor RelationsJuli P. Miller, Ph.D. - VP, Corporate Affairs and Investor RelationsT : +1 215 825 9310M : +1 215 460 8920Juli.Miller@adaptimmune.com. Media RelationsDana Lynch, Senior Director of Corporate CommunicationsM: +1 267 990 1217Dana.Lynch@adaptimmune.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/adaptimmune-participate-guggenheim-securities-smid-210000309.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adaptimmune-participate-guggenheim-securities-smid-210000309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SMID","ADAP","BK4011"],"gpt_icon":0},{"id":"2507647725","title":"ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507647725","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507647725?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:15","pubTimestamp":1738239300,"startTime":"0","endTime":"0","summary":"LAUSANNE, Switzerland, Jan. 30, 2025 /PRNewswire/ -- ADC Therapeutics SA , a commercial-stage global leader and pioneer in the field of antibody drug conjugates , today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025, at 2:00 p.m. ET.A live webcast of the presentation will be available via the Events & Presentations page in the IR section of the ADC Therapeutics website. A replay of the webcast will be available for approximately 30 days.About ADC TherapeuticsADC Therapeutics  is a commercial-stage global leader and pioneer in the field of antibody drug conjugates . The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.ZYNLONTA is a registered trademark of ADC Therapeutics SA.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/adc-therapeutics-participate-guggenheim-smid-121500438.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adc-therapeutics-participate-guggenheim-smid-121500438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4139","BK4080","BK4231","ADCT","SMID","ADC","BK4011","BK4505"],"gpt_icon":0},{"id":"2507664251","title":"Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507664251","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507664251?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:00","pubTimestamp":1738238400,"startTime":"0","endTime":"0","summary":"BOSTON, Jan. 30, 2025  -- Tango Therapeutics, Inc., a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim SMID Cap Biotechnology Conference on Wednesday, February 5, 2025 at 10:00 AM ET.Investor Contact: Daniella Beckman Chief Financial Officer, Tango TherapeuticsIR@tangotx.com. Media Contact: Daniella Beckman Chief Financial Officer, Tango Therapeuticsmedia@tangotx.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tango-therapeutics-present-guggenheim-smid-120000359.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4139","BK4011","TNGX","SMID"],"gpt_icon":0},{"id":"2507642861","title":"EyePoint to Present at Guggenheim SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507642861","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507642861?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:00","pubTimestamp":1738238400,"startTime":"0","endTime":"0","summary":"WATERTOWN, Mass., Jan. 30, 2025  -- EyePoint Pharmaceuticals, Inc. , a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025 at 9:30 a.m. ET.Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert Eto potentially improve outcomes in serious retinal diseases. The proven Durasertdrug delivery technology has been safely administered to thousands of patient eyes across fourU.S.FDA approved products.EyePoint Pharmaceuticalsis headquartered inWatertown, Massachusetts.DURAVYU has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential ap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eyepoint-present-guggenheim-smid-cap-120000292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1303367103.USD","BK4141","LU1951200564.SGD","BK4566","LU0889565833.HKD","LU1880398471.USD","LU2098885051.SGD","LU1242518931.SGD","LU1803068979.SGD","LU1242518857.USD","LU0390134368.USD","LU0719512351.SGD","LU1316542783.SGD","LU0642271901.SGD","IE0004445239.USD","LU0979878070.USD","BK4575","LU2458330243.SGD","LU1951198990.SGD","LU0889565916.HKD","IE00BMPRXN33.USD","IE00B5949003.HKD","LU0081259029.USD","LU2264538146.SGD","BK4011","LU0198837287.USD","LU1923623000.USD","LU0056508442.USD","LU0823434740.USD","LU0320765992.SGD","BK4534","LU1852331112.SGD","BK4532","LU0823421416.USD","BK4512","LU1064131342.USD","BK4007","SMID","LU0109394709.USD","BK4573","LU1988902786.USD","LU2250418816.HKD","LU0082616367.USD","IE0009356076.USD","BK4529","EYPT","BK4588","LU2054465674.USD","LU0109392836.USD"],"gpt_icon":1},{"id":"2507642708","title":"Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507642708","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507642708?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:00","pubTimestamp":1738238400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Jan.  30, 2025  (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that J","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/30/3017859/0/en/Beam-Therapeutics-to-Participate-in-Guggenheim-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4011","BK4139","LENZ","SMID"],"gpt_icon":0},{"id":"2507642058","title":"Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507642058","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507642058?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:00","pubTimestamp":1738238400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Jan. 30, 2025  -- Cullinan Therapeutics, Inc., a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference, being held in New York on February 5 and 6, 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cullinan-therapeutics-participate-fireside-chat-120000714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SMID","BK4139","CGEM","BK4011"],"gpt_icon":0},{"id":"2507517642","title":"Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507517642","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507517642?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:00","pubTimestamp":1738238400,"startTime":"0","endTime":"0","summary":"WATERTOWN, Mass., Jan. 30, 2025  -- Vigil Neuroscience, Inc. , a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025, at 10:30 a.m. ET.To register for the live webcast, please click here. The webcast will also be available on the Company’s website in the “Investors” section under “Events & Presentations.” An archived webcast will be available for approximately 90 days following the event.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vigil-neuroscience-present-guggenheim-securities-120000141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4011","SMID","VIGL"],"gpt_icon":0},{"id":"2507420556","title":"Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507420556","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507420556?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:00","pubTimestamp":1738238400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Jan.  30, 2025  (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc.(Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, tod","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/30/3017883/0/en/Cullinan-Therapeutics-to-Participate-in-Fireside-Chat-at-the-Guggenheim-Securities-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMID","CGEM","BK4139","BK4011"],"gpt_icon":0},{"id":"2507663054","title":"Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507663054","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507663054?lang=en_us&edition=fundamental","pubTime":"2025-01-30 05:05","pubTimestamp":1738184700,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Jan.  29, 2025  (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/29/3017572/0/en/Revolution-Medicines-to-Participate-in-the-Guggenheim-Securities-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1548497426.USD","LU2360107325.USD","ON","LU1720051108.HKD","LU2298322129.HKD","BK4588","LU1854103824.USD","LU1978683503.SGD","LU0124384867.USD","LU1861214812.USD","IE00BD6J9T35.USD","LU0724618433.USD","LU2357305700.SGD","LU1854104046.USD","LU1861220033.SGD","RVMD","LU1861219969.SGD","BK4141","LU1861215975.USD","LU0348723411.USD","MDCO","SMID","BK4011","BK4512","IE00BZ199S13.USD","BK4585","BK4139","LU1720051017.SGD"],"gpt_icon":0},{"id":"2507663809","title":"Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507663809","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507663809?lang=en_us&edition=fundamental","pubTime":"2025-01-29 21:00","pubTimestamp":1738155600,"startTime":"0","endTime":"0","summary":"PHILADELPHIA, Jan.  29, 2025  (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therap","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/29/3017090/0/en/Cabaletta-Bio-to-Participate-in-Guggenheim-s-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4011","SMID","CABA","BK4139"],"gpt_icon":0},{"id":"2507638909","title":"NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507638909","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507638909?lang=en_us&edition=fundamental","pubTime":"2025-01-29 21:00","pubTimestamp":1738155600,"startTime":"0","endTime":"0","summary":"NAARDEN, The Netherlands and MIAMI, Jan. 29, 2025  -- NewAmsterdam Pharma Company N.V. , a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease  with elevated low-density lipoprotein cholesterol , for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer of NewAmsterdam Pharma, will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 10:00 a.m. ET.NewAmsterdam Pharma  is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/newamsterdam-pharma-present-guggenheim-smid-130000812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4011","NAMS","NAMSW","SMID"],"gpt_icon":0},{"id":"2507638004","title":"CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507638004","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507638004?lang=en_us&edition=fundamental","pubTime":"2025-01-29 21:00","pubTimestamp":1738155600,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland and BOSTON, Jan.  29, 2025  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dis","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/29/3017123/0/en/CRISPR-Therapeutics-to-Present-at-the-Guggenheim-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","LU1861558580.USD","BK4588","BK4011","BK4556","LENZ","SMID","CRSP","LU1861559042.SGD"],"gpt_icon":0},{"id":"2507463849","title":"Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507463849","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507463849?lang=en_us&edition=fundamental","pubTime":"2025-01-29 21:00","pubTimestamp":1738155600,"startTime":"0","endTime":"0","summary":"FLORHAM PARK, N.J., Jan. 29, 2025  -- Phathom Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal  diseases, announced today that members of the management team will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Thursday, February 6, 2025, at 10:00 am ET.Company management will also participate in one-on-one meetings during the conference, which will run from February 5-6, 2025, in New York, NY.2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phathom-pharmaceuticals-present-guggenheim-securities-130000473.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4011","BK4007","PHAT","SMID"],"gpt_icon":0},{"id":"2507868047","title":"Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507868047","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507868047?lang=en_us&edition=fundamental","pubTime":"2025-01-29 20:30","pubTimestamp":1738153800,"startTime":"0","endTime":"0","summary":"BOSTON, January 29, 2025----Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025, at 1:00 pm EST.A live webcast of the fireside chat can be accessed under \"Events & Presentations\" in the Investors & Media section of the company’s website at www.verastem.com. A replay of the webcast will be archived on the website for approximately 90 days following the presentation.Verastem Oncology  is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verastem-oncology-present-guggenheim-smid-123000272.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4011","BK4139","SMID","VSTM"],"gpt_icon":0},{"id":"2507768066","title":"ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507768066","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507768066?lang=en_us&edition=fundamental","pubTime":"2025-01-29 20:30","pubTimestamp":1738153800,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Massachusetts, Jan.  29, 2025  (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/29/3017073/0/en/ProMIS-Neurosciences-to-Participate-in-Guggenheim-Securities-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4011","BK4143","MSA","LU2125909759.SGD","LU1815336091.USD","LU2211815571.USD","LU1923622291.USD","LU0053671581.USD","LU2125909916.SGD","SMID","LU0728928796.USD","LU0757428866.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":76,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SMID\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-27","symbol":"SMID","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1748318400000,"reportTimeType":"post","actualEps":0.27},{"market":"US","date":"2024-11-14","symbol":"SMID","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":0.59},{"market":"US","date":"2024-08-14","symbol":"SMID","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":0.37},{"market":"US","date":"2024-06-11","symbol":"SMID","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1718078400000,"reportTimeType":"post","actualEps":0.21},{"market":"US","date":"2024-05-23","symbol":"SMID","fiscalQuarterEnding":"2023/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1716436800000,"reportTimeType":"post","actualEps":0.04}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SMID\",market:\"US\",,,undefined,":[{"executeDate":"2015-12-16","recordDate":"2015-12-18","paymentDate":"2015-12-30","value":0.04,"currency":"USD"},{"executeDate":"2016-12-28","recordDate":"2016-12-30","paymentDate":"2017-01-13","value":0.01,"currency":"USD"},{"executeDate":"2018-12-18","recordDate":null,"paymentDate":null,"value":0.055,"currency":"USD"},{"executeDate":"2019-12-19","recordDate":"2019-12-20","paymentDate":null,"value":0.055,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SMID\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SMID\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SMID","date":"2025-06-13","current":20.354482,"percent":0.008772,"low":19.549057,"twenty":27.820298,"median":39.166482,"eighty":340.516225,"high":430.955547,"avg":137.971576,"sd":149.617182,"marketCap":156220646},"quantilePoints":[{"date":"2024-01-05","current":371.443946,"twenty":371.443946,"median":371.443946,"eighty":371.443946,"marketCap":211351605},{"date":"2024-01-12","current":364.577223,"twenty":364.394111,"median":366.316793,"eighty":371.443946,"marketCap":207444440},{"date":"2024-01-19","current":350.01977,"twenty":354.542651,"median":364.485667,"eighty":368.733879,"marketCap":199161249},{"date":"2024-01-26","current":383.98716,"twenty":357.893612,"median":365.950568,"eighty":375.14282,"marketCap":218488694},{"date":"2024-02-02","current":364.668779,"twenty":358.122503,"median":366.774575,"eighty":374.923085,"marketCap":207496535},{"date":"2024-02-09","current":411.911835,"twenty":362.526361,"median":368.056362,"eighty":380.398154,"marketCap":234377834},{"date":"2024-02-16","current":407.334019,"twenty":364.210998,"median":373.961745,"eighty":391.275043,"marketCap":231773057},{"date":"2024-02-23","current":402.481534,"twenty":364.503978,"median":375.838648,"eighty":397.766385,"marketCap":229011993},{"date":"2024-03-01","current":419.602564,"twenty":364.632157,"median":378.676895,"eighty":406.857926,"marketCap":238753859},{"date":"2024-03-08","current":288.310817,"twenty":361.574176,"median":376.708433,"eighty":406.436768,"marketCap":164048855},{"date":"2024-03-15","current":318.707511,"twenty":352.601658,"median":374.831529,"eighty":405.722628,"marketCap":181344574},{"date":"2024-03-22","current":406.143787,"twenty":354.487717,"median":375.838648,"eighty":405.649383,"marketCap":231095815},{"date":"2024-03-28","current":402.481534,"twenty":355.055367,"median":376.708433,"eighty":405.814184,"marketCap":229011993},{"date":"2024-04-05","current":402.847761,"twenty":356.932271,"median":379.500902,"eighty":406.986105,"marketCap":229220376},{"date":"2024-04-12","current":373.458185,"twenty":360.62199,"median":381.423584,"eighty":407.297396,"marketCap":212497707},{"date":"2024-04-19","current":343.610828,"twenty":356.932271,"median":377.852888,"eighty":406.986105,"marketCap":195514561},{"date":"2024-04-26","current":339.033012,"twenty":351.484671,"median":375.838648,"eighty":406.491701,"marketCap":192909784},{"date":"2024-05-03","current":338.8499,"twenty":338.923145,"median":373.458185,"eighty":406.253655,"marketCap":192805593},{"date":"2024-05-10","current":307.629199,"twenty":336.982151,"median":370.253714,"eighty":405.814184,"marketCap":175041014},{"date":"2024-05-17","current":335.096091,"twenty":332.679005,"median":367.781694,"eighty":404.330972,"marketCap":190669676},{"date":"2024-05-24","current":315.77771,"twenty":332.679005,"median":366.774574,"eighty":402.70127,"marketCap":179677517},{"date":"2024-05-31","current":243.243577,"twenty":329.675959,"median":365.675899,"eighty":402.481534,"marketCap":193378644},{"date":"2024-06-07","current":221.387574,"twenty":320.373836,"median":364.577223,"eighty":402.371667,"marketCap":176003121},{"date":"2024-06-14","current":103.82899,"twenty":307.629199,"median":364.394111,"eighty":401.932197,"marketCap":193329580},{"date":"2024-06-21","current":92.953443,"twenty":301.439992,"median":358.717619,"eighty":401.199747,"marketCap":173079310},{"date":"2024-06-28","current":78.505306,"twenty":301.000521,"median":355.742039,"eighty":400.888455,"marketCap":146176879},{"date":"2024-07-05","current":73.651635,"twenty":287.76148,"median":354.322916,"eighty":400.37574,"marketCap":137139344},{"date":"2024-07-12","current":83.612948,"twenty":243.243577,"median":351.255781,"eighty":396.026815,"marketCap":155687309},{"date":"2024-07-15","current":83.076786,"twenty":239.219562,"median":350.01977,"eighty":395.541567,"marketCap":154688976},{"date":"2024-08-02","current":95.239183,"twenty":237.221196,"median":347.181524,"eighty":395.056318,"marketCap":177335358},{"date":"2024-08-09","current":82.709939,"twenty":225.706685,"median":343.33616,"eighty":393.344215,"marketCap":154005907},{"date":"2024-08-16","current":36.655516,"twenty":102.484673,"median":340.269023,"eighty":392.11736,"marketCap":169531762},{"date":"2024-08-23","current":36.093702,"twenty":98.427931,"median":338.758344,"eighty":390.634149,"marketCap":166933371},{"date":"2024-08-30","current":40.221317,"twenty":87.349146,"median":337.018774,"eighty":388.253685,"marketCap":186023592},{"date":"2024-09-06","current":34.14455,"twenty":83.392839,"median":334.729866,"eighty":385.049213,"marketCap":157918545},{"date":"2024-09-13","current":37.435177,"twenty":80.491925,"median":332.349402,"eighty":384.426631,"marketCap":173137693},{"date":"2024-09-20","current":43.764187,"twenty":78.211828,"median":329.785826,"eighty":383.858981,"marketCap":202409364},{"date":"2024-09-27","current":39.584976,"twenty":74.057989,"median":329.053374,"eighty":382.577192,"marketCap":183080516},{"date":"2024-10-04","current":35.715337,"twenty":43.489013,"median":317.242611,"eighty":379.336101,"marketCap":165183434},{"date":"2024-10-11","current":39.670968,"twenty":41.202772,"median":307.629199,"eighty":378.512094,"marketCap":183478229},{"date":"2024-10-18","current":37.607161,"twenty":40.301576,"median":302.822492,"eighty":377.688086,"marketCap":173933119},{"date":"2024-10-25","current":36.804569,"twenty":39.673261,"median":300.945587,"eighty":376.900701,"marketCap":170221131},{"date":"2024-10-31","current":38.742255,"twenty":39.338466,"median":288.310817,"eighty":376.387986,"marketCap":179182929},{"date":"2024-11-08","current":41.562792,"twenty":39.269672,"median":262.6784,"eighty":375.289311,"marketCap":192227913},{"date":"2024-11-15","current":27.789331,"twenty":39.269672,"median":243.243577,"eighty":374.831529,"marketCap":180852964},{"date":"2024-11-22","current":36.655839,"twenty":38.673461,"median":236.428563,"eighty":373.458185,"marketCap":238556197},{"date":"2024-11-29","current":40.013376,"twenty":38.554219,"median":226.952073,"eighty":373.165205,"marketCap":260407054},{"date":"2024-12-06","current":38.799121,"twenty":38.554219,"median":221.387574,"eighty":371.773549,"marketCap":252504681},{"date":"2024-12-13","current":40.518637,"twenty":38.574497,"median":102.708726,"eighty":369.539575,"marketCap":263695290},{"date":"2024-12-20","current":35.669766,"twenty":38.301976,"median":99.671306,"eighty":368.257786,"marketCap":232138834},{"date":"2024-12-27","current":38.090127,"twenty":38.160211,"median":97.750675,"eighty":367.891561,"marketCap":247890544},{"date":"2025-01-03","current":35.8735,"twenty":38.026802,"median":93.122757,"eighty":367.708449,"marketCap":233464736},{"date":"2025-01-10","current":32.41002,"twenty":37.861697,"median":83.612948,"eighty":367.561959,"marketCap":210924410},{"date":"2025-01-17","current":33.363496,"twenty":37.645079,"median":83.401305,"eighty":367.159111,"marketCap":217129629},{"date":"2025-01-24","current":33.550931,"twenty":37.458108,"median":82.893362,"eighty":366.13368,"marketCap":218349459},{"date":"2025-01-31","current":33.070118,"twenty":37.40078,"median":80.480637,"eighty":365.950568,"marketCap":215220331},{"date":"2025-02-07","current":30.584563,"twenty":36.919225,"median":78.67462,"eighty":365.40123,"marketCap":199044333},{"date":"2025-02-14","current":30.454173,"twenty":36.655516,"median":76.445317,"eighty":364.668779,"marketCap":198195756},{"date":"2025-02-21","current":30.242289,"twenty":36.093702,"median":75.683404,"eighty":364.595534,"marketCap":196816818},{"date":"2025-02-28","current":27.715986,"twenty":35.893058,"median":73.313007,"eighty":364.430733,"marketCap":180375640},{"date":"2025-03-07","current":27.618194,"twenty":35.775708,"median":43.420219,"eighty":364.394111,"marketCap":179739207},{"date":"2025-03-14","current":26.526179,"twenty":35.319343,"median":42.738016,"eighty":363.66166,"marketCap":172632375},{"date":"2025-03-21","current":26.884751,"twenty":34.845366,"median":42.227797,"eighty":359.669805,"marketCap":174965961},{"date":"2025-03-28","current":28.661313,"twenty":34.002405,"median":41.774906,"eighty":356.337155,"marketCap":186527823},{"date":"2025-04-04","current":22.402601,"twenty":33.539522,"median":41.195893,"eighty":354.826476,"marketCap":145796128},{"date":"2025-04-11","current":23.902084,"twenty":33.350457,"median":40.914787,"eighty":354.37785,"marketCap":155554763},{"date":"2025-04-17","current":24.334,"twenty":32.876164,"median":40.680642,"eighty":353.93838,"marketCap":158365675},{"date":"2025-04-25","current":24.47254,"twenty":32.35516,"median":40.221317,"eighty":352.967884,"marketCap":159267288},{"date":"2025-05-02","current":23.975428,"twenty":31.735252,"median":40.013376,"eighty":351.008578,"marketCap":156032088},{"date":"2025-05-09","current":24.945203,"twenty":30.61879,"median":39.79709,"eighty":346.613875,"marketCap":162343379},{"date":"2025-05-16","current":26.477283,"twenty":30.330302,"median":39.676701,"eighty":343.903808,"marketCap":172314158},{"date":"2025-05-23","current":24.888157,"twenty":29.277404,"median":39.646655,"eighty":343.446027,"marketCap":161972127},{"date":"2025-05-30","current":25.580853,"twenty":28.56352,"median":39.584976,"eighty":343.079802,"marketCap":166480192},{"date":"2025-06-06","current":20.50958,"twenty":28.125085,"median":39.295176,"eighty":342.219172,"marketCap":157411026},{"date":"2025-06-13","current":20.354482,"twenty":27.820298,"median":39.166482,"eighty":340.516225,"marketCap":156220646}],"updateTime":1750144817241}}}